Li Zhongxin followed Li Chengfeng listlessly and began to think about it. Now that he arrived at Li Chengfeng's office, what benefits could he get from this old man!

Li Zhongxin suddenly thought that Li Chengfeng was the minister of the Ministry of Machinery and had worked in central ministries and commissions for many years. He should have had a lot of contact with institutions like the State Patent Office. Since the matter of Zhongxin Scientific Research Base has been told to Li Chengfeng and he has given all the benefits to the Ministry of Machinery, he should also let Li Chengfeng bleed and study the State Patent Office for him.

In China, the patentee who issues patent certificates to grant patent rights is the State Patent Office. The State Patent Office enjoys exclusive rights (also known as monopoly or exclusive rights) for manufacturing, use, and sales (some countries also include importing the patent invention or design) within the period stipulated by law.

Others must have the consent of the patent owner to commit the above-mentioned acts, otherwise it will be infringement. After the patent term expires, the patent right will be extinguished. Anyone can use the invention or design for free.

China! It was proposed in 1984 and started trial operation on April 1, 1985. In order to protect the legitimate rights and interests of patent owners, encourage inventions and creations, promote the application of inventions and creations, improve innovation capabilities, promote scientific and technological progress and economic and social development, the Patent Law was formulated.

The purpose of China's promulgation and implementation of the Patent Law is to promote active investment in market resources in a direction that is conducive to the continuous emergence of inventions and creations, and to promote the prosperity and development of economic industries.

To this end, the state grants inventors a monopoly right within a certain period of time through legal procedures, and at the same time requires them to disclose the content of the invention to the whole society, so as to increase the willingness of market individuals to invent and create, while promoting the rapid accumulation and development of the overall technical level of society.

Li Zhongxin's patented injection molding technology was registered internationally because China had not yet established such a thing as the National Patent Office at that time.

Li Zhongxin clearly remembers in his heart that in the next few decades, China has been plundered by patent institutions around the world because of patent issues.

Some Chinese scientific research institutions do not have much understanding of patent law and patents, and they all think that in China, patents are of little use.

Moreover, they think it would be a terrible thing to spend such a large amount of money to obtain patent certification.

Develop something that can obtain patent protection, basically emptying the assets of these researchers. They have no money or want to find someone to get some money to register a patent.

As long as the things they have developed can be listed in advance and occupy the market in advance, as for the subsequent things, even if someone imitates them, they don’t have much to worry about.

In China, the trend of using politicism is very serious, and this is also one of the biggest reasons why China's counterfeits have been rampant in countless years to come.

R&D requires a lot of cost, and whether the developed things can make money is unknown.

However, if you use known money-making things to imitate production, the cost of the things produced will naturally be low. Then, they will be able to quickly occupy the market and will not care whether the thing enjoys patent rights.

It is this idea that made China suffer a great loss in the high-end and the ownership of patent rights in later generations, and even after paying a bloody price, it was understood the importance of patents.

Li Zhongxin remembers it very clearly that in later generations, his family’s relatives suffered from lung cancer.

When it is found that it is lung cancer, it is already in the late stage of lung cancer.

At this time! After the consultation of the attending doctor, the relatives began targeted treatment.

The first generation of targeted therapeutic drugs for lung cancer is called Iresa. This thing is a drug developed by developed Western countries. In the international market, it costs tens of thousands of yuan per box for Chinese people to buy the genuine Iresa, while the Indian version of Iresa is only sold for a few hundred yuan per box in India.

When Chinese people want to take such drugs, they basically spend the most expensive money to buy them, or go to India to buy them.

The biggest reason for this is that China did not have enough understanding of patent law at that time and did not have the right to use patents to purchase such drugs. Moreover, China would not have implemented a patent compulsory licensing system like India, that is, in special circumstances, it can be granted by the government and licensed other companies to use a certain patent without the consent of the patent owner.

In other words, when the poor cannot afford a high-priced patented drug, India allows the drug to be directly copied regardless of whether the patent protection period ends.

The Indian government did this to break the monopoly of European and American pharmaceuticals and to make life-saving drugs for the poor, but this is actually an act of ignoring the intellectual property rights of drugs. Behind it is the robber logic of "I am poor, so I have reason, you have money, so you should let me imitate it."

Patent protection is a common norm around the world and a law that everyone abides by.

Of course, other countries can copy generic drugs, but India does not have the confidence to not abide by the rules. However, its non-compliance with the rules directly benefiting the ordinary people who cannot afford high-priced drugs.

This puts generic drugs in a dilemma: it is certainly impeccable morally, but it is legally illegal.

Many people may not know how much money and manpower it will take to launch a new drug, how many failures and repeated experiments will take, and the clinical trial stage.

This cost is extremely huge and ordinary companies cannot afford it. The investment cost of developing a special drug by several major well-known pharmaceutical companies in the world, such as Pfizer, Switzerland, and Bayer, Switzerland, Germany, and other major companies is as high as billions or even tens of billions of dollars.

This investment will be distributed to the drug price after the new drug is launched, so new specialty drugs are often very expensive because they include R&D costs.

However, Indian generic drugs directly bypass the research and development stage and can be made into biosimilar within 3 months of the launch of the original drug. This generic drug may have the effect of only about 80% of the original drug, but the price is only 1/10 of the original drug.

For example, the special drug for the treatment of chronic myeloid leukemia is "Gleevec" developed by Swiss Novartis, which costs about 23,000 yuan per box, while its generic drug VEENAT is only more than 200 yuan and is produced by Indian pharmaceutical company Natco. The active ingredient of the two is imatinib, but the price difference is huge.

In addition to Gleevec, other special drugs such as Herceptin for breast cancer, Iresa for lung cancer, and Dojime for renal cell carcinoma and liver cancer, India has their generic drugs.
Chapter completed!